McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Am J Hum Genet. 2018 Jun 7;102(6):1062-1077. doi: 10.1016/j.ajhg.2018.04.003. Epub 2018 May 24.
Missense DNA variants have variable effects upon protein function. Consequently, interpreting their pathogenicity is challenging, especially when they are associated with disease variability. To determine the degree to which functional assays inform interpretation, we analyzed 48 CFTR missense variants associated with variable expressivity of cystic fibrosis (CF). We assessed function in a native isogenic context by evaluating CFTR mutants that were stably expressed in the genome of a human airway cell line devoid of endogenous CFTR expression. 21 of 29 variants associated with full expressivity of the CF phenotype generated <10% wild-type CFTR (WT-CFTR) function, a conservative threshold for the development of life-limiting CF lung disease, and five variants had moderately decreased function (10% to ∼25% WT-CFTR). The remaining three variants in this group unexpectedly had >25% WT-CFTR function; two were higher than 75% WT-CFTR. As expected, 14 of 19 variants associated with partial expressivity of CF had >25% WT-CFTR function; however, four had minimal to no effect on CFTR function (>75% WT-CFTR). Thus, 6 of 48 (13%) missense variants believed to be disease causing did not alter CFTR function. Functional studies substantially refined pathogenicity assignment with expert annotation and criteria from the American College of Medical Genetics and Genomics and Association for Molecular Pathology. However, four algorithms (CADD, REVEL, SIFT, and PolyPhen-2) could not differentiate between variants that caused severe, moderate, or minimal reduction in function. In the setting of variable expressivity, these results indicate that functional assays are essential for accurate interpretation of missense variants and that current prediction tools should be used with caution.
错义 DNA 变异对蛋白质功能有不同的影响。因此,解释它们的致病性具有挑战性,尤其是当它们与疾病的可变性相关时。为了确定功能测定在多大程度上可以提供解释,我们分析了 48 种与囊性纤维化(CF)表现度可变相关的 CFTR 错义变体。我们通过评估在缺乏内源性 CFTR 表达的人类气道细胞系基因组中稳定表达的 CFTR 突变体,在天然同基因背景下评估功能。与 CF 表型完全表达相关的 29 种变体中的 21 种产生了<10%的野生型 CFTR(WT-CFTR)功能,这是发展为危及生命的 CF 肺部疾病的保守阈值,而 5 种变体的功能中等降低(10%至∼25%WT-CFTR)。该组中其余的三种变体出人意料地具有>25%的 WT-CFTR 功能;其中两个高于 75%WT-CFTR。正如预期的那样,与 CF 部分表达相关的 19 种变体中的 14 种具有>25%的 WT-CFTR 功能;然而,有四种变体对 CFTR 功能几乎没有影响(>75%WT-CFTR)。因此,在 48 种被认为是致病的错义变体中,有 6 种(13%)没有改变 CFTR 功能。功能研究通过专家注释和美国医学遗传学和基因组学学院以及分子病理学协会的标准,大大完善了致病性的分配。然而,四种算法(CADD、REVEL、SIFT 和 PolyPhen-2)无法区分导致功能严重、中度或轻微降低的变体。在表达度可变的情况下,这些结果表明功能测定对于正确解释错义变体至关重要,并且应该谨慎使用当前的预测工具。